Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz Sells 20,000 Shares

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $27.66, for a total transaction of $553,200.00. Following the completion of the transaction, the director now owns 3,462,584 shares of the company’s stock, valued at approximately $95,775,073.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Simulations Plus Trading Up 7.8 %

Shares of NASDAQ:SLP opened at $30.82 on Thursday. The firm has a market cap of $618.56 million, a price-to-earnings ratio of 62.90 and a beta of 0.71. Simulations Plus, Inc. has a 1 year low of $27.22 and a 1 year high of $51.22. The business has a fifty day simple moving average of $31.82 and a 200 day simple moving average of $39.60.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. The business had revenue of $18.70 million during the quarter, compared to analyst estimates of $19.73 million. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The firm’s revenue was up 19.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.18 EPS. On average, sell-side analysts forecast that Simulations Plus, Inc. will post 1.11 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on SLP shares. BTIG Research decreased their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Wednesday. KeyCorp started coverage on Simulations Plus in a research report on Monday, July 29th. They set an “overweight” rating and a $47.00 price target on the stock. StockNews.com downgraded Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday. Finally, JMP Securities initiated coverage on Simulations Plus in a research note on Tuesday, July 16th. They set a “market perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $54.50.

Institutional Trading of Simulations Plus

Large investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio acquired a new stake in shares of Simulations Plus in the 1st quarter valued at $1,082,000. Silvercrest Asset Management Group LLC bought a new position in Simulations Plus during the first quarter valued at about $4,717,000. Deerfield Management Company L.P. Series C acquired a new stake in shares of Simulations Plus in the second quarter worth about $811,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Simulations Plus during the 1st quarter worth about $70,000. Finally, Tributary Capital Management LLC increased its holdings in shares of Simulations Plus by 54.7% during the 3rd quarter. Tributary Capital Management LLC now owns 325,567 shares of the technology company’s stock valued at $10,425,000 after acquiring an additional 115,122 shares during the last quarter. 78.08% of the stock is owned by institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.